• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email
    New Drug Application (NDA): 217603
    Company: TARSUS PHARMACEUTICALS, INC.
    • Email

    Products on NDA 217603

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    SOLUTION/DROPS;OPHTHALMIC Prescription None No No
    SOLUTION/DROPS;OPHTHALMIC Prescription None No No
    XDEMVY LOTILANER 0.25% SOLUTION/DROPS;OPHTHALMIC Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 217603

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    07/24/2023 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217603Orig1s000ltr.pdf
    Get the next $TARS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    8/1/2022$40.00Overweight
    Barclays
    12/21/2021$40.00Buy
    HC Wainwright & Co.
    11/23/2021$55.00Outperform
    Oppenheimer
    10/8/2021$50.00 → $65.00Strong Buy
    Raymond James
    6/29/2021$39.00 → $50.00Strong Buy
    Raymond James
    More analyst ratings

    $TARS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      5/7/25 11:27:44 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.

      10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

      5/1/25 4:10:36 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

      5/1/25 4:07:27 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO and Board Chair Azamian Bobak R. sold $300,000 worth of shares (6,000 units at $50.00) (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/26/25 4:47:19 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Mottiwala Aziz sold $505,856 worth of shares (10,565 units at $47.88), decreasing direct ownership by 14% to 65,057 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:54 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Neervannan Seshadri sold $363,142 worth of shares (7,583 units at $47.89), decreasing direct ownership by 9% to 79,682 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

      Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:29:16 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

      SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:41:12 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:35:55 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 3:05:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tarsus Pharmaceuticals with a new price target

      Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00

      11/20/23 7:55:38 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Tarsus Pharmaceuticals with a new price target

      William Blair initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $44.00

      7/18/23 7:27:56 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Tarsus Pharmaceuticals

      Guggenheim initiated coverage of Tarsus Pharmaceuticals with a rating of Buy

      5/18/23 7:36:58 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tarsus to Participate in Upcoming Investor Conferences

      IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20th, at 12:00 p.m. PT / 3:00 p.m. ETStifel Virtual Ophthalmology Forum on Tuesday, May 27th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours a

      5/8/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      12/19/23 6:30:59 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Financials

    Live finance-specific insights

    See more
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad

      4/24/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

      Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; first pharmacologic treatment to demonstrate functional improvements in Meibomian Gland Disease and patient symptoms in Demodex blepharitis patients Continued advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, the next category-creating opportunity in eye care Management to host conference call today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced

      2/25/25 7:00:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Leadership Updates

    Live Leadership Updates

    See more
    • Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

      Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access

      11/13/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

      IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris

      11/5/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

      IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra

      4/24/23 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care